Expression profiling of IDH-mutant low-grade gliomas treated with TMZ identified a three-lncRNA signature (including HOXD-AS2 and H19-related lncRNAs) that is correlated with TMZ resistance and progression-free survival [22,62,64]. Here, IDH1 is linked to central nervous system cancer.